A non-canonical repressor function of JUN restrains YAP activity and liver cancer growth
Yes-associated protein (YAP) and its homolog, transcriptional coactivator with PDZ-binding motif (TAZ), are the main transcriptional downstream effectors of the Hippo pathway. Decreased Hippo pathway activity leads to nuclear translocation of YAP/TAZ where they interact with TEAD transcription factors to induce target gene expression. Unrestrained YAP/TAZ activity can lead to excessive growth and tumor formation in a short time, underscoring the evolutionary need for tight control of these two transcriptional coactivators. Here, we report that the AP-1 component JUN acts as specific repressor of YAP/TAZ at joint target sites to decrease YAP/TAZ activity. This function of JUN is independent of its heterodimeric AP-1 partner FOS and the canonical AP-1 function. Since expression of JUN is itself induced by YAP/TAZ, our work identifies a JUN-dependent negative feedback loop that buffers YAP/TAZ activity at joint genomic sites. This negative feedback loop gets disrupted in liver cancer to unlock the full oncogenic potential of YAP/TAZ. Our results thus demonstrate an additional layer of control for the interplay of YAP/TAZ and AP-1.
Authors
- Kyungmok Kim (ORCID: https://orcid.org/0000-0003-2037-3333)
- Marco Jessen (ORCID: https://orcid.org/0000-0001-5234-4786)
- Björn von Eyß (ORCID: https://orcid.org/0000-0002-4731-6841)
- Yuliya Kurlishchuk
- Paul Cramer
- Christin Ritter
- Anita Cindric Vranesic
- Alexandra Kipping
Institutions
- Leibniz Association (DE)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
Publication Details
- Journal
- The EMBO Journal
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1038/s44318-024-00188-0
- Citations
- 4
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 1.30
Funders
- Alexander von Humboldt-Stiftung
- Wilhelm Sander-Stiftung
- Australian Government
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Deutsche Krebshilfe
- Leibniz-Gemeinschaft